On the 30 June 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,394 million and NAV per share was SEK 39.14. Return on NAV* in the month was -2.1%.

Allocation of NAVShare of portfolio companyFair value (MSEK)Part of NAV per share (SEK)Share of NAVProduct Development    Lipum100%3484.0110.3%Prokarium50%2873.318.5%KAHR Medical34%2092.416.2%Empros Pharma79%2042.366.0%Atrogi44%1972.275.8%Bonsai Biotherapeutics100%1581.824.6%Microbiotica10%1291.483.8%Xspray Pharma17%1191.383.5%Xintela60%1021.173.0%Mendus23%810.942.4%AnaCardio13%790.922.3%Geneos Therapeutics12%700.802.1%Vitara Biomedical11%550.631.6%EpiEndo Pharmaceuticals9%550.631.6%Buzzard Pharmaceuticals15%330.381.0%Egetis Therapeutics1%290.330.8%Amarna Therapeutics58%110.130.3%Strike Pharma18%110.120.3%Total 2,17725.1264.2%Commercial Growth    Symcel30%2042.366.0%NorthX Biologics61%2022.335.9%Chromafora28%1371.594.1%Nanologica50%790.912.3%Frontier Biosolutions2%270.310.8%Bohus Biotech45%220.260.7%Total 6727.7519.8%Assets related to Portfolio companies 2372.747.0%Other assets and liabilities 3073.549.1%Net Asset Value 3,39439.14100.0% 

* Following the bonus issue of 11,888,785 shares conducted in May and followed by a cancellation of 8,412,578 shares in June, the return for the month is calculated on total NAV instead of as previously NAV per share.

For more information:

Ted Fjällman, CEO

Email:

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments